Articles: chronic.
-
Respiratory Support PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Non invasive ventilation (NIV) ia a technical support in patients with acute or chronic respiratory failure. The NIV is used in patients with obesity hypoventilation syndrome (OHS) presenting with hypercapnic respiratory failure. Few studies examine the evolution and impact after starting this therapy in this patient group Objectives: To evaluate the result of non invasive ventilation started in obese patients in acute hypercapnic respiratory failure (AHRF) and its prognosis consequences. Asses the impact of long-term NIVMETHODS: Observational study with consecutive inclusion of obese patients with AHRF treated with NIV from February 2008 to June 2011. Obesity: BMI>30kg/m; AHRF: pH<7.35 and PaCO2> 45mmHg. Treatment: NIV started in general or respiratory wards and emergency department ⋯ The following authors have nothing to disclose: Concepcion Romero, Jesús Sánchez, Virginia Almadana, Ana Gómez-Bastero, Patricia Guerrero, Agustin Valido, Jose María Benítez, Teodoro MontemayorNo Product/Research Disclosure Information.
-
Critical care medicine · Mar 2014
Multicenter Study Observational StudyAugmented Renal Clearance in the ICU: Results of a Multicenter Observational Study of Renal Function in Critically Ill Patients With Normal Plasma Creatinine Concentrations.
To describe the prevalence and natural history of augmented renal clearance in a cohort of recently admitted critically ill patients with normal plasma creatinine concentrations. ⋯ Augmented renal clearance appears to be a common finding in this patient group, with sustained elevation of creatinine clearance throughout the first week in ICU. Future studies should focus on the implications for accurate dosing of renally eliminated pharmaceuticals in patients with augmented renal clearance, in addition to the potential impact on individual clinical outcomes.
-
Late Breaking AbstractsSESSION TYPE: Slide PresentationPRESENTED ON: Saturday, March 22, 2014 at 09:00 AM - 10:00 AMPURPOSE: Human immunodeficiency virus seropositivity (HIV+) has been considered a contraindication to lung transplantation (LT) primarily due to potential risks of iatrogenic immunosuppression. With the recent passage of the HIV Organ Policy Equity (HOPE) Act on November 21, 2013, the donation of HIV+ organs for transplant in HIV+ recipients is now legal in the USA. As a result there may be an increase in donors for HIV+ recipients. However, there remains only one fully published case report of LT in an HIV+ patient, limiting the evidence base with which to guide medical decision making. We report 3 HIV+ patients at two different medical centers who underwent LT. ⋯ The following authors have nothing to disclose: Ryan Kern, Harish Seethamraju, Paul Blanc, Neeraj Sinha, Matthias Loebe, Jeffrey Golden, Jasleen Kukreja, Scott Scheinin, Steve Hays, Kleinhenz Mary Ellen, Leard Lorri, Charles Hoopes, Jonathan SingerNo Product/Research Disclosure Information.
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Treatment guidelines for chronic obstructive pulmonary disease (COPD) recommend combination therapy of 2 or more long-acting bronchodilators with different mechanisms of action. Here we report the long-term safety of a fixed-dose combination of aclidinium bromide, a long-acting muscarinic antagonist indicated for maintenance treatment of COPD-associated bronchospasm, with formoterol fumarate, a long-acting β2-agonist, in patients with COPD. ⋯ Barry Make: Consultant fee, speaker bureau, advisory committee, etc.: Barry Make received payment for service on the advisory boards of Forest Pharmaceuticals, AstraZeneca, Novartis, Merck, Boehringer Ingelheim, Pfizer, Ikaria, and GlaxoSmithKline, consulting fees from Astellas Pharma, and Talecris Biotherapeutics, lecture fees from GlaxoSmithKline, Boehringer Ingelheim, Pfizer, and Forest Pharmaceuticals, payment for video presentation preparation from Boehringer Ingelheim and Pfizer, payment for document reviews from Spiration., Grant monies (from industry related sources): Barry Make received grant support from AstraZeneca, GlaxoSmithKline, Pfizer, Nabi Biopharmaceuticals, Boehringer Ingelheim, Forest, and Sunovion, Grant monies (from sources other than industry): Barry Make received grant support from the National Heart Lung, and Blood Institute, James Donohue: Consultant fee, speaker bureau, advisory committee, etc.: Dr. Donohue has received consultant/speaker/advisory fees from Novartis, GlaxoSmithKline, Boehringer-Ingelheim, Forest and Pfizer Xiaoyun Zhong: Employee: X. Zhong is an employee of Forest Research Institute, Inc. Anne Leselbaum: Employee: Anne Leselbaum is an employee of Almirall S.A. Cynthia Caracta: Employee: Cynthia Caracta is an employee of Forest Research Institute, Inc., Shareholder: Cynthia Caracta is is a stockowner and has received stock options from Forest Laboratories, Inc.Aclidinium bromide (Tudorzo/Pressair, Eklira/Genuair, Breo/Ellipta) is approved for the maintenance treatment of COPD-associated bronchspasm. The fixed-dose combination of aclidinium bromide/formoterol fumarate is being developed, but not yet approved, for its commercial use for the treatment of COPD.
-
Pleural Disease/Pneumothorax PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Pneumothorax continues to be a major cause of morbidity and mortality among the respiratory patients but there is paucity of data regarding aetiology, clinical profile, management and outcome of Spontaneous Pneumothorax (SP) from this part of the world. Therefore, this study was carried out to determine the aetiology, clinical presentation, management and outcomes of Spontaneous pneumothorax in a tertiary care Hospital from eastern India. ⋯ The following authors have nothing to disclose: Aparup Dhua, Sourin Bhuniya, Arunabha Datta Chaudhuri, Sumit Raytapadar, Tapan Das BairagyaNo Product/Research Disclosure Information.